Roger E.
Susi, CEO, President, and Chairman of IRADIMED CORPORATION (NASDAQ:IRMD), reported the indirect sale of 7,500 shares of common stock across multiple open-market transactions on May 26, 2026 and May 27, 2026, according to a SEC Form 4 filing
Transaction summary Transaction value based on SEC Form 4 weighted average purchase price ($92.14); post-transaction value as reported in SEC Form 4 was $0.00 using the May 27, 2026 trade-date close price. Key questions – How does the transaction compare to Susi’s historical sale sizes and patterns? This 7,500-share sale aligns with Susi’s recent cadence of smaller, routine block sales; over the past year, his average sale size has ranged from 5,000 to 10,000 shares, with this transaction reflecting the reduced share capacity as his holdings have declined. – What proportion of Roger Susi’s indirect holdings were affected?
This transaction left the Phillip Susi 2008 Dynasty Trust with approximately 2.16 million shares post-sale. – Was this a direct or indirect disposition, and are there any remaining derivative awards? All shares sold were via indirect holdings (trust); no direct ownership or outstanding options remain following the transaction as of the filing date. – What market context is relevant for this transaction? The sales were executed under a Rule 10b5-1 plan during a period when IRADIMED CORPORATION had posted a 77.2% one-year total return (as of May 27, 2026), with the sale price near recent highs and reflecting ongoing systematic liquidation rather than discretionary trading.